Tracy S. Anderson has established an impressive career in the medical market by integrating his expertise as a skilled surgical technician with his corporate experience. A graduate of the University of Georgia, Anderson began working in the medical industry as a Cardiopulmonary Systems Specialist with Baxter Healthcare. After Baxter, he helped develop two intraocular lens companies, Ioptex, Inc. and Chiron, from the ground up. In 2002, Mr. Anderson founded Atlanta based T2MED, Inc., one of the Southeast’s most innovative private companies in the growing spinal device market. In 2008, Anderson merged T2 into Amendia, Inc., as one of its founding partners. With Anderson as the President of its Sales and Marketing group, Amendia grew to over $85 MM in sales before being acquired by private equity for $190 MM. In December of 2012, Anderson licensed a unique stem cell lineage from the University of Miami for potential use in general orthopaedics. In March of 2013, Vivex Biologics was spun out from Amendia as a freestanding entity. In November of 2014, Anderson was instrumental in the acquisition of the University of Miami Tissue Bank, the oldest and one of the most prestigious human tissue facilities in the world. UMTB immediately became a fully owned subsidiary of Vivex Biologics, Inc. In October of 2018, Anderson transitioned from his role as President and CEO to the role of Vice Chairman. He remains a member of the Board of Directors and Chair of its Board of Governors. Through his leadership and innovation, Vivex has grown to become a leading tissue and cell therapy company with scientifically-based technologies, an unsurpassed patent portfolio, and significant revenue in the spine and orthopaedic space.
Throughout his career, Anderson has partnered with some of the medical industry’s top experts in the areas of general orthopaedics, spine surgery, sports medicine, cardiovascular surgery, ophthalmic surgery, and oncology. He is a member of several other professional organizations and advisory boards including the Advisory Committee for Surgical Technology at Gwinnett Tech in Lawrenceville, Georgia.
Prior to joining MRLV, Diana was an Associate at Flagship Pioneering where she was a member of the company creation team. Diana contributed to conceiving and building companies, leading efforts to develop corporate vision and strategy as well as raising seed funding. Prior to her role at Flagship, Diana completed her Ph.D. in Pharmacology at the University of Pennsylvania focused on the role of epigenetics in diabetes and developed a technology to alter gene expression by targeted epigenetic modifications as a novel treatment strategy.
Prior to obtaining her Ph.D., Diana was a project manager at Sigma-Tau Pharmaceuticals (now Leadiant Biosciences), defining and driving many aspects of drug development for rare disease programs. Prior to joining Sigma-Tau, she was an Associate in PricewaterhouseCoopers Health Industry Advisory practice focused on merging operations in support of a large biotech acquisition.
Joe Cook, III co-founded Mountain Group Partners (MGP) in 2002. Since that time, MGP has grown from a single-family office to a venture capital firm, investing on behalf of its own private capital accounts and several large family offices. MGP invests in early stage companies in the Life Sciences industry (diagnostics/med tech, expedited drug development, and agtech) and Technology industry (healthcare technology and business technology).
Prior to his involvement with MGP, Mr. Cook was a Director, Private Placements in the Investment Banking Group of Robert W. Baird & Co. in Nashville from January 2001 through February 2003. During this time, he helped originate and led the team executing nine transactions raising almost $400 million. Previously, Mr. Cook was a Vice President in the Investment Banking Group at J.C. Bradford & Co. in Nashville. Mr. Cook graduated with a B.A. in Economics from Davidson College, and moved to Nashville, TN in 1993. Mr. Cook is married to Ashley Cook and they have two sons.
Mr. Cook currently serves on or has visitation rights to the board of directors of: Castle Biosciences, (NASDAQ: CSTL) a company developing and commercializing molecular diagnostics to aid healthcare professionals in assessing probability of tumor progression to metastasis and improving information for therapy choices; Cerebrotech, a company that has developed a non-invasive monitoring device for early detection of cerebral bleeding and edema; Lineagen, a chromosomal microarray and next generation sequencing genetic testing company serving children and families with autism and other developmental delays; and MiNDERA, a company developing a proprietary method for extracting skin biomarkers which enable non-invasive molecular testing for skin cancer and other skin diseases.
Mr. Cook previously served on or had visitation rights to the board of directors of: Diagnovus, a molecular diagnostic company targeting rare and orphan diseases; and OnFocus Healthcare, a company selling proprietary performance management software to hospitals and other healthcare organizations.
Mr. Cook has previously served on the boards of the Martha O’Bryan Center, St. Paul Christian Academy and Ten Thousand Villages of Nashville. Mr. Cook also serves on the Board of Southeast BIO, a regional non-profit organization that fosters the growth of the life sciences industry in the Southeastern U.S.
Andrew Krouse has over a decade of biotech investing and leadership experience with a track record of success as the founder and CEO of Tau Therapeutics, LLC, Xdynia LLC, and venture backed Cavion, Inc. He has been recognized for his leadership in the industry as a CIT GAP 50 Entrepreneur in the Commonwealth of Virginia, a member of the Board of SEBIO, and is the immediate past Chairman of the Virginia Biotechnology Association. Prior to his experience in the pharmaceutical industry, he worked as an analyst for Goldman Sachs, NYC, and served as Vice President of the UVA Darden Graduate School of Business. Most recently, he led the acquisition of UVA startup, Cavion, to industry leader Jazz Pharmaceuticals.
Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”). While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries.
Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.
Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has also served on the boards of Biotechnology Industry Association, Harvard Kennedy School – M-R CBG Advisory Council, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member and The University of Delaware Lerner College NYC Dean’s Council.
Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.
Dr. Behanna is currently a principal at SR One, and previously acted as a principal at Sofinnova Investments, focused on investments in innovative therapeutics. Prior to joining Sofinnova, Dr. Behanna was a senior vice president and biotechnology sell-side analyst at Wedbush Securities, preceded by a role as an associate at JMP Securities. Her other experience includes early stage drug discovery at the Astellas Research Institute and a role as adjunct professor at the Feinberg School of Medicine at Northwestern University. Dr. Behanna received her Ph.D. in Chemistry from Northwestern University, an M.S. in Organic Chemistry from the Weizmann Institute of Science and her B.S. from Tufts University.
Gerry Brunk is a Managing Director at Lumira Ventures, a North American healthcare venture capital firm. Since joining the firm in 2002 to open its Boston office he has invested in and served on the boards of directors of over 25 life science companies, including Pharmasset (acquired by Gilead Sciences), MAKO Surgical (acquired by Stryker), Corvia Medical, Satsuma Pharmaceuticals (Nasdaq: STSA), enGene, KAI Pharmaceuticals (acquired by Amgen), Endotronix, HistoSonics and Engage Therapeutics.
Before joining Lumira Ventures, Gerry was an entrepreneur who co-founded and served in a variety of management and board capacities at start-up companies in the pharmacy benefit management, senior living and technology transfer sectors. He was previously an engagement manager in the healthcare practice of The Boston Consulting Group and a member of the investment banking group of Credit Suisse First Boston where his clients included public and private healthcare companies.
Gerry holds an MBA from Stanford Graduate School of Business and a BA from the University of Virginia, where he studied biology and economics.
Dr. De La Rosa is the Chief Executive Officer, a board member, and a co-founder of Antios Therapeutics. He was most recently the Chief Scientific Officer of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD), focused on the discovery and development of antiviral drugs for the treatment of viral diseases of unmet medical need and global concern. During his nearly 6-year tenure at Emory University, he helped raise over $40 million in funding and was a co-inventor on technologies licensed to AbbVie and Antios Therapeutics.
Prior to joining Emory University, Dr. De La Rosa was Senior Vice President of Business Development and Scientific Affairs at Pharmasset. From 2002 until its acquisition by Gilead Sciences (NASDAQ: GILD) for $11 billion in 2012, he was responsible for licensing, strategic transactions, and alliance management of collaborations and partnerships with pharmaceutical companies and universities. He provided business and scientific leadership to drug development programs for the treatment of HIV, Hepatitis B and Hepatitis C, including Sofosbuvir. Prior to Pharmasset, Dr. De La Rosa held both scientific and business positions at Visible Genetics, where he was responsible for the development and improvement of genotyping tests for HIV, Hepatitis B and Hepatitis C, including the first sequencing-based HIV drug resistance test to receive FDA approval. He also held scientific positions at Innogenetics, Boston Biomedica, and Digene, developing molecular diagnostic tests for infectious diseases. He is an inventor and author on several U.S. patents and publications relating to molecular diagnostic methods, techniques and therapeutics for infectious diseases and cancer.
Dr. De La Rosa has served on Scientific Advisory Boards and Board of Directors of biotechnology companies. He currently serves on the Board of Directors of Celtaxys.
Dr. De La Rosa earned a Fogarty Fellowship and an Intramural Research Training Award Fellowship from the National Institutes of Health, where he completed post-doctoral training in the Laboratory of Biochemistry and the Laboratory of Pathology of the National Cancer Institute. He holds a Bachelor’s Degree in Microbiology from the University of California, San Diego, and a Ph.D. in Microbiology from Miami University.
Ron Lattanze is the Chief Executive Officer of Lucerno Dynamics, LLC and is based in Research Triangle Park, North Carolina. Ron has 26 years of cross-functional experiences in the medical device industry. Ron enjoys managing organizations faced with challenging, complex problems. He recruits top talent, builds teams, and focuses on executing creative and game-changing strategies that generate great results. Since 2012, Ron has been the CEO of Lucerno, where he and the team have built a disruptive platform technology on a simple idea – quantifying nuclear medicine insight to improve patient outcomes and lower healthcare costs.
Prior to joining Lucerno, Ron consulted for six years with medical device companies and private equity firms. Before consulting, Ron’s career rose rapidly at Guidant Corporation, a $4B cardiovascular medical device firm. Ron ran Guidant’s multi-link stent operations, creating a lean and nimble manufacturing team that could take raw material and produce finished goods ready for distribution within 36 hours. After directing stent operations, Ron spent three years setting up Guidant’s Asia business, based in Hong Kong. After managing 15 Guidant operations in Asia, Ron was promoted to Chief Operating Officer of Guidant Japan. Within months he was promoted to President Guidant Japan and joined Guidant’s Management Committee. In Japan Ron initiated the Harmonization by Doing effort, between the Japanese MHLW, FDA, and Duke University, to dramatically speed up the Japanese medical device regulatory process for Guidant’s US designed products. He also created a Japanese development organization that brought a Japan-only product to market in less than 11 months. After nearly four years in Tokyo, Ron returned to the U.S. to run Guidant’s fastest growing business Endovascular Solutions. Within 2 weeks of arriving, Ron unleased the creative capacity of the team and the invention disclosure rate jumped 21x in less than six months. When Guidant was purchased by Abbott and Boston Scientific in 2006, Ron retired to North Carolina to help raise his young family and begin his consulting practice.
In the past seven years, Ron recruited a small and talented team that has taken an idea from concept to commercialization. During this period, he has moved beyond cardiology and now feels comfortable developing products for the nuclear medicine, oncology, rheumatology, and neurology markets; many of which have $1B+ in annual revenue potential. He has also authored several clinical papers and holds several patents. Ron has a B.A. and an MBA from the University of North Carolina at Chapel Hill and served as a Naval Officer for seven years.
Carol Schafer is the Managing Partner of Hyphen Advisors, LLC. Hyphen Advisors provides advisory, consulting and board services to public and private companies on topics such as financing strategy and execution, financial planning, investor access and messaging, and strategic initiatives.
Until September 2018, Carol was a Vice Chair in Equity Capital Markets at Wells Fargo Securities where she was responsible for healthcare origination and execution. She joined Wells Fargo Securities in 2007. Prior to this, she spent 17 years at J.P. Morgan, where she was a Managing Director in Equity Capital Markets covering healthcare, chemical, consumer and retail companies. Between her Equity Capital Markets roles, she served as Vice President of Finance and Business Development for Lexicon Genetics Incorporated.
Carol currently serves on the Board of Directors at Idera Pharmaceuticals, Five Prime Therapeutics and Repare Therapeutics. She earned a B.A. from Boston College and an M.B.A. from New York University.
Brent R. Bellows, Ph.D., Esq., is a Partner with Knowles Intellectual Property Strategies, LLC focusing on pharmaceutical and biotechnology patent prosecution and portfolio management. Dr. Bellows brings a wealth of knowledge in international patent law to implement worldwide strategies that maximize the value of patent portfolios around clinical assets. Dr. Bellows regularly speaks on IP policy issues, and is an author or co-author on a number of patent policy focused articles. He is actively involved in the IP community, and recently served as the Chair of the IP Section of the State Bar of Georgia. Dr. Bellows has been recognized by IAM Magazine as one of the top 300 IP Strategists in the world. Prior to joining KIPS in 2011 as a partner, Dr. Bellows practiced at King & Spalding, LLP in Atlanta, Georgia, and served as a law clerk for the Honorable Charles A. Pannell Jr. in the Federal District Court for the Northern District of Georgia.
Tom has been a venture partner with HealthQuest since 2012, where he leverages his training as a physician, experience in the diagnostics industry and success as one of the industry’s best executive recruiters and management team builders. He currently serves as a board member of HealthQuest portfolio company InMediata and an observer for BioIQ and Lineagen.
Tom founded Life Science Partner, a very successful executive recruiting firm that has helped build the leadership teams at some of the world’s foremost medical device and pharmaceutical companies, as well as many venture-backed companies in the medical device, biotech and healthcare services sectors.
Prior to LSP, he led similar practices at Korn/Ferry and Russell Reynolds. Tom has learned that the quality of a company’s management team predicts it’s success more than products or technologies and that perspective guides him in looking at companies for HealthQuest.
Tom began his career at Roche Molecular, where he developed and implemented their first marketing programs around PCR for medical diagnostics, including HIV detection. Like all HealthQuest partners he then worked inside a start-up, SyStemix where he established technology developmental partnerships with major cancer centers including MD Anderson, Fred Hutchinson Cancer Research Center and the Mayo Clinic. SyStemix developed proprietary stem cell purifying technologies important for treatment of cancer and genetic illnesses. He was the liaison with Sandoz’s oncology group, whose parent company completed its acquisition of the company in 1996.
Tom has been especially active at promoting the industry across his home state of Georgia and the entire southeast. He is former Chairman of Georgia Bio, co-founder of SEMDA, the Southeast Medical Device Association and serves on the boards of SEBIO and the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Tech.
Tom earned his MD from Vanderbilt and both his undergraduate degree and MBA from Duke University. He lives in Atlanta and splits his free time between hiking/skiing in the mountains and kite-boarding on the coast.
Jon is a Partner at Medicxi and a member of the co-founding team. Prior to joining Medicxi, Jon was an Associate at Index Ventures for two years, having joined in 2014. He led Medicxi’s investment in Synthorx and currently serves on the boards of a number of portfolio companies, including Palladio Biosciences, Xenikos, Z-Factor, UltraHuman, Breakpoint Therapeutics, Phathom Pharmaceuticals and Sydnexis. Jon was also previously a director of Impact Biomedicines (acquired by Celgene).
Prior to Index, Jon was a life sciences strategy consultant at ClearView Healthcare Partners.
Jon received a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and conducted postdoctoral research at MIT.
Mr. McCallum has a diverse background focused on founding and building organizations. Mr. McCallum most recently worked at Goldman Sachs & Co. in the Investment Management Division advising high net worth families. The majority of his clients at Goldman Sachs owned and operated middle market businesses and Mr. McCallum spent a considerable part of his time providing clients with strategic advice for their business. Prior to working Goldman Sachs, Mr. McCallum served as the CEO of several ventures in both the for-profit and non-profit sectors. From 1993 until 1996, McCallum served as a Legislative Aide to the Speaker of the United States House of Representatives, the Honorable Newt Gingrich, in Washington, DC.
Mr. McCallum completed graduate studies at Harvard University obtaining a Master in Public Administration from the Kennedy School of Government. Mr. McCallum received his undergraduate degree from Washington and Lee University obtaining a Bachelor of Science in Commerce. While at Washington and Lee, Mr. McCallum was twice selected as an NCAA All-America football player and was a member of the Dean’s List. John and his wife Heather reside on St. Simons Island, Georgia and have four young boys John, James, Wilson and Liam.
An experienced entrepreneur with a strong scientific and operational background, Sue brings a decade of experience in pharmaceutical management and research with Abbott Labs and Eli Lilly & Company and more than 16 years of senior management experience with entrepreneurial firms in Florida including three start-ups. At AGTC, Sue has successfully secured investments of more than $91 million from nationally recognized venture capitalists and granting agencies; negotiated and closed on a major collaboration with a top five Biotech company; lead the company to complete critical milestones; and recruited an experienced management team. Her experience as a group leader with Abbott’s Diagnostic Division helped hone her skills in bringing new products and technologies from the lab bench into the market place.
Sue is the chair of Southeast BIO, is a member of the Executive Committee of BioFlorida and sits on the board of the Florida High Tech Corridor Council. She has a degree in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Warrington College of Business Entrepreneurship program.
Lou developed the original concept and is the founding partner of OUP. Lou is also managing director of Texelerate, LLC, a technology transfer consultancy he formed in 2005 to assist academic institutions, entrepreneurs, and investors in licensing transactions and in monetizing their intellectual property assets. Lou is also lead advisor, non-profit institutions for HealthCare Royalty Partners.
Lou is a former Managing Director of the Center for Technology Transfer of the University of Pennsylvania and the former Director of Licensing and Business Development for Virginia’s Center for Innovative Technology. Lou is a Past President of AUTM (Association of University Technology Managers) and active member of LES (Licensing Executives Society). He has been a founder, director, and/or CEO of several start-ups including Biotherapeutics, InnoTech, and TMune Therapeutics.
Lou has been involved in intellectual property licensing, business development, and entrepreneurial activities for 30+ years. He is a Certified Licensing Professional (CLP) and Registered Technology Transfer Professional (RTTP). He has testified as an expert in intellectual property litigation in federal and state courts.
Lou has a baccalaureate degree from the Penn State, a teaching credential from UCSB, and masters and doctoral degrees from Teachers College, Columbia University.
Lou resides in Naples, FL with his wife Harriet.
molecular diagnostics, life sciences, and therapeutics. She is the CEO of Editas Medicine, a publicly-traded gene editing company. Prior to Editas she served as the CEO of Human Longevity Inc. (HLI), and before HLI she served as the CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics, Inc. Prior to GE, Ms. Collins served as President and CEO of GenVec, a publicly-traded vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses. Prior to Beckman Coulter, she served as President and CEO of Sequoia Pharmaceuticals, Inc., a venture-capital funded company developing HIV and HCV therapeutics. Earlier, Ms. Collins served as President of Clinical Micro Sensors, Inc., a wholly-owned subsidiary of Motorola, where she directed the development and commercialization of a molecular diagnostic platform. Prior to Motorola, she spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President & General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. She began her career with Abbott Laboratories where she spent 6 years in various operating roles. Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA, from The University of Chicago Booth School of Business.
Ms. Collins is a member of the board of directors for Editas Medicine, ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics, DermTech, and Biocare Medical.
John Gustofson is a Managing Director of AbbVie Ventures and invests across AbbVie’s therapy areas of Immunology, Oncology, and Neuroscience. He currently serves on the Board of Disarm, Ribometrix and Rheostat and is a Board Observer for Ribon Therapeutics.
Prior to joining AbbVie, John worked at AstraZeneca as a Director of Strategic Partnering and Business Development focused on oncology licensing. John has 20+ years professional experience as a bench scientist and in various roles of market and business development. In addition, John has worked in numerous biotechnology companies including Altus Pharmaceuticals, Therion Biologics, Boston Life Sciences and Ribozyme Pharmaceuticals. John also spent approximately 4 years in strategy consulting to the life sciences industry.
He holds a Masters Degree in Molecular Biology from the Miami University and an MBA from the Boston University.
Gladys Nunez joined Amgen in 1997 and currently leads diligence and completion of venture investments. Prior to Amgen Ventures in 2014, Gladys spent over 10 years in Amgen’s Technology licensing group prospecting, negotiating and establishing external alliances support for Amgen’s R&D organization. Prior to joining business development Gladys worked 7 years in R&D, concurrent between Amgen and AstraZeneca. Gladys holds an MS in Biochemical Pharmacology from the University of Southhampton in England.
Mr. Wehrly is a seasoned leader in the medical device and biotech industries that consistently delivers top-line growth and operational efficiencies. Prior to joining Vivex Biologics as CEO, Mr. Wehrly was the former CEO and Chairman of the Board of Synaptive Medical, a privately held Toronto-based company that focused on uniting highly innovative technology with the medical device industry for neuro-cranial and spinal markets. Mr. Wehrly was previously Group President, heading the global business in Western Europe, Japan, Canada, Australia and New Zealand for Covidien. Prior to Covidien, he held various general management positions within Medtronic Inc., including Senior Vice-President, President Spinal & Biologics and President of Medtronic Sofamor Danek. Additionally, Mr. Wehrly spent 17 years with DePuy Orthopedics, a Johnson & Johnson company where he served numerous roles of increasing responsibilities including VP of Sales & Marketing and President of DePuy OrthoTech. Mr. Wehrly has held numerous board positions at for profit and not-for-profit organizations. He earned his BS in Management from Ball State University and has completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland.